Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
Status:
Recruiting
Trial end date:
2021-12-05
Target enrollment:
Participant gender:
Summary
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on
Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient
population.